Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized vs Standard 177Lu-DOTATOC in NETs
NCT04915144Phase 2Withdrawn
- Sponsor
- BC Cancer
- Start
- Jan 2023
- Primary completion
- Dec 2027
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium Lu 177-edotreotide in neuroendocrine tumors (NETs) (2 arms), sponsored by BC Cancer. Primary endpoints: Adverse Events at 8 months and Progression-Free Survival at 12 months. Planned start Jan 2023; status: withdrawn.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT04915144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04915144.